BioMoti

BioMoti seeks to transform the treatment of cancer by targeted delivery of therapeutics to the intracellular space of cancer cells

One in three of us will get cancer and increases in life expectancy indices will exacerbate this statistic in the future. Most current chemotherapeutics have devastating side effects including hair loss, nausea, weakened immunity and fatigue to name but a few. BioMoti exists to transform the treatment of cancer patients by doing things differently. BioMoti seeks to transform the treatment of cancer by targeted delivery of therapeutics to the intracellular space of cancer cells; aiming to dramatically increase efficacy whilst reducing side effects. Oncojans are a new class of therapeutic microparticles that target and gain entry to the interior of cancer cells where they slowly release drugs at the point of need whilst sparing healthy tissue. The Oncojan platform is compatible with a range of drug classes from small molecule therapeutics to larger biologicals. MOTI1001 is BioMoti’s lead Oncojan based ovarian cancer candidate that has shown very promising potential in early preclinical studies.